About our writing
The opinions expressed in The Lawrentian are those of the students, faculty and community members who wrote them. The Lawrentian does not endorse any opinions piece except for the staff editorial, which represents a majority of the editorial board. The Lawrentian welcomes everyone to submit their own opinions using the parameters outlined in the editorial policy.
We learn what the driving force is behind some of this year s upcoming games as developers speak out about their game inspirations. On the run-up to the
DGAP-News: Marinomed Biotech AG berichtet Finanzergebnisse für das 1 Quartal 2021: Umsatzwachstum durch anhaltend starke Nachfrage nach Carragelose-basierten Virusblockern finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
RBmedia Announces Exclusive Audiobook Partnership with Prestigious New Publisher Levine Querido
Share Article
Through this three-year agreement, the company will expand its award-winning 3,000-title children’s and young adult audiobook catalogue with Levine Querido titles
Levine Querido is a publisher you dream about working with in this industry. Arthur and his powerhouse team publish a highly curated list of beautiful works by underrepresented and global voices. LANDOVER, Md. (PRWEB) May 25, 2021 RBmedia, the largest audiobook producer in the world, today announced its partnership with independent children’s publisher Levine Querido. Through this agreement, the company will add audio editions of the Levine Querido titles to its award-winning and sizable children’s and young adult catalog over the next three years in both the English- and Spanish-language markets.
DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
The poster
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER) , Abstract TPS2658
, will present CatalYm s first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment. In the GDFATHER-trial, patients with advanced-stage, solid tumors who have not responded or stopped responding to anti-PD-1/PD-L1 therapy are treated with CTL-002 as monotherapy and followed by combination with an anti-PD-1 antibody. The first patient was enrolled in December 2020.